AD 5467: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 197383 |
CHEMBL ID | 164603 |
SCHEMBL ID | 1219564 |
MeSH ID | M0179604 |
Synonym |
---|
ad 5467 |
bdbm50040782 |
(2,8-diisopropyl-3-thioxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-acetic acid |
ad-5467 |
MAYBRIDGE4_002198 |
NCGC00176814-01 |
HMS1527D20 |
BRD-A80280426-001-01-2 |
CHEMBL164603 , |
2-[2,8-di(propan-2-yl)-3-sulfanylidene-1,4-benzoxazin-4-yl]acetic acid |
2h-1,4-benzoxazine-4-acetic acid, 3,4-dihydro-2,8-diisopropyl-3-thioxo- |
3,4-dihydro-2,8-diisopropyl-3-thioxo-2h-1,4-benzoxazine-4-acetic acid |
138333-32-1 |
112808-22-7 |
SCHEMBL1219564 |
CLDJCRWXLDLJLO-UHFFFAOYSA-N |
(2,8-diisopropyl-3-thioxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)acetic acid |
CCG-250702 |
AKOS030552636 |
[2,8-di(propan-2-yl)-3-sulfanylidene-2,3-dihydro-4h-1,4-benzoxazin-4-yl]acetic acid |
DTXSID40930059 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.1300 | 0.0004 | 1.8773 | 10.0000 | AID34961 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID34961 | Inhibitory activity against purified rat lens aldose reductase (RLAR) | 1994 | Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6 | Molecular modeling studies of aldose reductase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |